HC Wainwright Predicts Higher Earnings for Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for Dyne Therapeutics in a research report issued to clients and investors on Tuesday, March 3rd. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings per share of ($3.05) for the year, up from their previous estimate of ($3.17). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($0.76) EPS, FY2027 earnings at ($1.68) EPS, FY2028 earnings at ($0.08) EPS, FY2029 earnings at $1.28 EPS and FY2030 earnings at $3.24 EPS.

Several other brokerages have also issued reports on DYN. Chardan Capital reiterated a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday. Royal Bank Of Canada lifted their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Robert W. Baird set a $30.00 price target on shares of Dyne Therapeutics in a report on Monday, December 8th. JPMorgan Chase & Co. dropped their price objective on shares of Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, December 8th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.00.

Dyne Therapeutics Stock Down 0.2%

Shares of Dyne Therapeutics stock opened at $15.20 on Friday. The company has a market capitalization of $2.51 billion, a P/E ratio of -4.29 and a beta of 1.34. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 13.47. The business has a 50-day moving average of $17.15 and a two-hundred day moving average of $17.03. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.02).

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Aberdeen Group plc grew its holdings in shares of Dyne Therapeutics by 15.0% in the 3rd quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after acquiring an additional 72,770 shares in the last quarter. Saturn V Capital Management LP bought a new stake in Dyne Therapeutics during the second quarter worth about $13,856,000. Arcadia Investment Management Corp MI boosted its position in Dyne Therapeutics by 23.1% during the second quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock valued at $526,000 after purchasing an additional 10,350 shares during the last quarter. Vanguard Group Inc. boosted its position in Dyne Therapeutics by 27.6% during the third quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after purchasing an additional 2,109,257 shares during the last quarter. Finally, Squarepoint Ops LLC grew its stake in Dyne Therapeutics by 334.3% in the second quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock valued at $1,730,000 after purchasing an additional 139,896 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a “Buy” rating and a lofty $50 price target, and raised its FY2026 loss forecast slightly (smaller loss, from ($3.17) to ($3.05)) — this keeps a strong upside narrative for longer‑term investors. MarketBeat Report
• Neutral Sentiment: HC Wainwright also published a longer EPS path showing a return to profitability by FY2029–FY2030 (FY2030: $3.24 EPS), which supports a growth thesis but is far‑term and model‑sensitive. MarketBeat Report
• Neutral Sentiment: Reported short interest data is effectively zero/unchanged (likely a reporting quirk) and does not appear to be a market driver.
• Negative Sentiment: HC Wainwright trimmed medium‑term forecasts (FY2027–FY2029 and FY2028 revisions), lowering expected EPS in some years — this reduces near‑term profitability expectations and can weigh on sentiment. MarketBeat Report
• Negative Sentiment: Lifesci Capital made small downward revisions to several quarterly estimates (Q2 and Q4 2026, and others with mixed tweaks), which modestly increases near‑term uncertainty around upcoming results. MarketBeat Report

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.